Skip to main content
PMC home page
Oncotarget logoLink to Oncotarget
. 2016 May 27;7(25):37636–37648. doi: 10.18632/oncotarget.9400

Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders

Elizabeth Margolskee 1, Vaidehi Jobanputra 1, Preti Jain 1, Jinli Chen 1, Karthik Ganapathi 1, Odelia Nahum 1, Brynn Levy 1, Julie Morscio 2, Vundavalli Murty 1, Thomas Tousseyn 2, Bachir Alobeid 1, Mahesh Mansukhani 1,#, Govind Bhagat 1,#
PMCID: PMC5122338  PMID: 27203213

Abstract

Post-transplant lymphoproliferative disorders of T- or NK-cell origin (T/NK-PTLD) are rare entities and their genetic basis is unclear. We performed targeted sequencing of 465 cancer-related genes and high-resolution copy number analysis in 17 T-PTLD and 2 NK-PTLD cases. Overall, 377 variants were detected, with an average of 20 variants per case. Mutations of epigenetic modifier genes (TET2, KMT2C, KMT2D, DNMT3A, ARID1B, ARID2, KDM6B, n=11). and inactivation of TP53 by mutation and/or deletion(n=6) were the most frequent alterations, seen across disease subtypes, followed by mutations of JAK/STAT pathway genes (n=5). Novel variants, including mutations in TBX3 (n=3), MED12 (n=3) and MTOR (n=1), were observed as well. High-level microsatellite instability was seen in 1 of 14 (7%) cases, which had a heterozygous PMS2 mutation. Complex copy number changes were detected in 8 of 16 (50%) cases and disease subtype-specific aberrations were also identified. In contrast to B-cell PTLDs, the molecular and genomic alterations observed in T/NK-PTLD appear similar to those reported for peripheral T-cell lymphomas occurring in immunocompetent hosts, which may suggest common genetic mechanisms of lymphoma development.

Keywords: post-transplant lymphoproliferative disorders, immunodeficiency, genetic, genomic, T-cell lymphoma

INTRODUCTION

Post-transplant lymphoproliferative disorders (PTLD) encompass morphologically heterogeneous entities with variable clinical behavior. [1] PTLDs of B-lineage predominate, while T- and NK-cell PTLDs (T/NK-PTLD) are rare, representing 2-15% of all cases. [2] T/NK-PTLDs usually present late after transplantation, are associated with a poor prognosis, and, in contrast to B-cell PTLDs, only a minority are EBV-related (up to 37%). [2, 3]

The pathogenesis of T/NK-PTLDs and the underlying molecular alterations are presently unknown and their relationship to peripheral T-cell lymphomas (PTCL) arising in immunocompetent hosts remains unclear. Hence, in order to gain insights into the genetic bases of these uncommon PTLDs, we performed targeted next generation sequencing of cancer-associated genes and genome-wide DNA profiling to assess copy number alterations in a relatively large series of well characterized T/NK-PTLDs. We observed frequent mutations of epigenetic modifiers, members of the JAK/STAT signaling cascade, and TP53, and recurrent genomic alterations, similar to those described in PTCL arising in immunocompetent individuals.

RESULTS

Morphology and immunophenotype

All T- and NK-cell lymphomas were classified based on morphologic and immunophenotypic features according to the 2008 WHO guidelines. [4] Immunophenotypic analysis was based on a combination of flow cytometry and immunohistochemistry. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) was the most common subtype (n = 6, 32%), followed by hepatosplenic T-cell lymphoma (HSTCL; n = 3), primary cutaneous anaplastic large cell lymphoma (c-ALCL; n = 3), angioimmunoblastic T-cell lymphoma (AITL; n = 2), extranodal NK/T-cell lymphoma, nasal type (ENKTCL; n = 2), EBV-positive peripheral T-cell lymphoma (EBV+ PTCL; n = 1), lymphomatoid papulosis (LyP; n = 1) and adult T-cell leukemia/lymphoma (ATLL; n = 1) (Table 1, representative cases are illustrated in Figure 1).

Table 1. Clinical, morphological and immunohistochemical data.

Case Age/Sex Underlying dx Graft IS therapy Time to PTLD (y) Diagnosis Location CD2 CD3 CD5 CD7 CD4 CD8 CD56 TIA CD30 EBER Ki-67 Other B-catenin MLH1 MSH2 PMS2 MSH6 Gata3 Lineage MSI status TCR Treatment Status Survival (days)
1 75F Viral CM Heart AZA+CS+P 15.01 PTCL, NOS BM + - + - - + - + ND - 30% ND ND ND ND ND ND ND MSS Clonal VMP Dead 66
2 29M Viral CM Heart AZA+CS+P 12.62 PTCL, NOS Subcutaneous tissue, face + + + - + - - ND - - ND PD1- - + + + - - ND MSI-H Clonal CHOP/RT, gemcitabine Dead 197
3 57M Hypersensitivity pneumonitis Left lung CNI+MMF+P 0.47 PTCL, NOS Subcarinal LN + + +/− − − + − + − − 80% CD10-, CD15-, PD1-, CD25-, MUM1- − + + + + − αβ MSS Clonal EPOCH Dead 98
4 75M Dilated CM Heart CNI+MMF+P 2.00 PTCL, NOS Retroperitoneum + + +/− +/− + − − − − − 40% ALK-, BCL2-, MUM1-, PD1- ND ND ND ND ND ND ND ND Clonal Cytoxan/Etoposide Dead 29
5 41F Post-partum CM Heart CNI+P+MMF 7.01 PTCL, NOS Retroperitoneum + + + − + − − − − − ND CD10-, BCL2+, PD1+, MUM1- − + + + + − αβ MSS PC EPOCH, GEMOX, Pralatrexate, Radiation and Auto-SCT Alive 976
6 32F CHF Heart CS 14.01 EBV+ PTCL Breasts, bilateral + + + − +/− + − + + + 70% CD10-, ALK-, MUM1- ND ND ND ND ND ND ND MSS Clonal EPOCH, Radiation and gemcitabine Alive 1405
7 32M N/A Liver CNI+AZA+CS 5.83 HSTCL Spleen, liver, BM + + − + − + + + − − ND − + + + + γδ MSS Clonal VDMCT Dead 120
8 34M Dilated CM Heart AZA+CS+P 9.73 HSTCL Spleen ND + − − − + ND + − − ND − + + − + − γδ MSS Clonal CHOP, ESHAP, MNM Dead 273
9 35M GN, NOS Kidney AZA+CS+P 10.01 HSTCL Spleen, liver + + − ND − − + + ND ND ND PD1- − − + + + 70% γδ MSS Clonal CHOP Dead 70
10 57F DM Kidney n/a 24.43 AITL Retroperitoneum + + + − + − ND ND − − 50% BCL6+, CD10+, PD1+ − + + + + 30% αβ MSS PC RCHOP/Gemcitabine/Pralatrexate Dead 321
11 44M N/A Lung CNI+CS 4.08 AITL LN, lung + + + + + − − ND − -* ND BCL6+, PD1+ ND + + + + ND ND MSS Clonal Rituximab Dead 730
12 83M N/A Kidney CNI+MMF+CS 6.92 Primary cutaneous ALCL, CD30+ Skin, pleura + − − − + − ND − + − ND ALK- − + + + + ND ND MSS ND CHOP Dead 120
13 47M Nephrogenic systemic fibrosis Kidney CNI+MMF 4.73 Primary cutaneous ALCL, CD30+ Skin, back + − − − + − ND − + − 80% ALK-, BCL2+ − + + + + 80% αβ MSS Clonal CHOP/RT Dead 3839
14 71M N/A Heart CNI+AZA+CS 18.00 Primary cutaneous ALCL, CD30+ Skin + − − − + − ND − + − ND ALK- ND ND ND ND ND ND ND ND Clonal CHOP Dead 210
15 20F Drug induced CM Heart AZA+CS+P 5.49 ENKTCL Right breast + + − + − − + + − + 70% CD25+ − + + + + − -- MSS PC N/A Dead 18
16 71F Hypersensitivity pneumonitis Lung CNI+AZA+P 7.40 ENKTCL Nasal vestibule, lung + + + +/− − + − + − + 90% ND ND ND ND ND ND αβ ND Clonal None Dead 61
17 43F FSGS Kidney CNI+AZA+P 6.98 ATLL Retroperitoneum + − − − + − − ND + − ND ALK-, FoxP3-, CD25+, MUM1+ ND ND ND ND ND ND ND ND Clonal EPOCH X4 Alive 650
18 83M APCKD Kidney CNI+MMF 3.23 Lymphomatoid papulosis Skin, left forearm + − − − − − − ND + − ND CD15+, ALK-, MUM1+ ND ND ND ND ND ND ND ND PC Reduced IS Alive 2741
19 70M N/A Kidney CNI+AZA+CS 1.92 PTCL, NOS Pleura, pericardium, LN + + − − + − − − − − ND ALK- ND ND ND ND ND ND ND MSS Clonal None Dead 60
Open in a new tab

Immunosuppression; MSI: Microsatellite instability; TCR: T-cell receptor clonality; CM: Cardiomyopathy; CHD: Congestive heart failure; GN: Glomerulonephritis; DM: Diabetes Mellitus; FSGS: Focal segmental glomerulosclerosis; APCKD: Autosomal dominant polycystic kidney disease; LN: Lymph node; BM: Bone marrow; AZA: Azathioprine; CS: Corticosteroids; P: Prednisone; CNI: Calcineurin inhibitor; MMF: Mycophenolate mofetil; RT: Radiotherapy; N/A: Not available; ND: Not done; PC: Polyclonal;

*

EBER+ B-cells were present

Figure 1. Histopathologic and phenotypic features of selected subtypes of T/NK-PTLD.

Figure 1

Open in a new tab

A. and B. EBV+ PTCL in the breast; CD8+ and EBER+. C. and D. PTCL, NOS presenting as a retroperitoneal mass; CD4+ and PD1+. E. and F. Hepatosplenic T-cell lymphoma in the spleen; TCR-gamma+. G. and H. PTCL, NOS in subcarinal lymph node; CD8+.

PTCL, NOS (n = 6) comprised CD4+ and CD8+ cases with downregulation or loss of CD7 seen in all. One CD8+ T-cell lymphoma expressed CD30 and showed evidence of EBV infection by in situ hybridization for EBER. The three cases of HSTCL were derived from TCR-gamma-delta T-cells. They expressed TIA-1 but not the cytotoxic granule constituents (granzyme-B, perforin) and lacked CD5 expression. The AITL cases were CD4+ and displayed expanded and disrupted follicular dendritic cell meshworks. One case had a concomitant EBV+ clonal B-cell proliferation. The c-ALCL cases showed diffuse dermal infiltrates of large CD30+ T-cells, many exhibiting prominent nucleoli, and lacked ALK expression. Both ENKTCL were EBV+. One was of cytotoxic T-cell origin involving the breast and the other of NK-cell origin involving the nasal vestibule and lung; both displayed cellular atypia, had high proliferation indices and showed angiodestruction and extensive necrosis. The ATLL presented as lymphomatous disease and the neoplastic cells expressed CD4 and CD25.

Clinical characteristics

The detailed clinical features of the 19 T/NK-PTLD are described in Table 1. The median age was 47 (range: 20-83) and 12/19 (63%) patients were male. The most commonly transplanted organ was heart (n = 8), followed by kidney (n = 7), lung (n = 3) and liver (n = 1). Immunosuppressive therapy comprised calcineurin inhibitors (n = 12), corticosteroids (n = 11), azathioprine (n = 10), and mycophenolate mofitil (n = 6); no association between the type of therapy and organ allograft was observed. The median interval between organ transplantation and diagnosis was 7 years (range: 0.5 - 18 y). Extranodal disease was seen in 15/19 (79%) cases and 3 (16%) cases were EBV+. The types of therapies for PTLD and response to treatment varied. The patient with lymphomatoid papulosis (case 18) was treated with reduction in immunosuppression alone, which led to disease regression. Four patients received a combination of chemotherapy and radiation and 12 received chemotherapy alone. Two patients were referred for palliative care. Clinical remission was achieved in 1 patient with c-ALCL (case 13) who presented with localized disease, after treatment with chemotherapy and radiation; he died of disease unrelated causes 12 years post diagnosis. One patient with EBV+ PTCL (case 6) is in remission 4 years after diagnosis having received chemotherapy with etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) and one individual with PTCL, NOS (case 5) achieved remission after chemotherapy, radiation, and allogeneic stem cell transplantation. The patient diagnosed with ATLL, based on positive serology for HTLV-1, was treated with EPOCH and is alive 2 years after diagnosis. Despite aggressive treatment, however, the median overall survival was 6.6 months (range: 18 days to 12 years).

Genome-wide copy number alterations

Copy number alterations were observed in 12/16 cases (75%; complex = 8, simple = 4). Loss of heterozygosity was noted in 7/16 (44%) cases (Figure 3F; Table 2). No recurrent alterations were seen in 5 cases of PTCL, NOS. Two of three HSTCL showed 7q gain and 7p loss, indicative of isochromosome 7q. One of two ENKTCL showed loss of 6q. Copy number alterations in 1 of 2 cases of c-ALCL analyzed included 1p gain and losses at 13q and 16q. No copy number changes were detected in the ATLL and lymphomatoid papulosis.

Figure 3. Schematic representation of the types and locations of TP53, STAT3 and STAT5b mutations.

Figure 3

Open in a new tab

A. TP53 mutations. B. Table showing T/NK-PTLD subtypes with TP53 mutation and 17p copy number changes. C. STAT3 mutations in the SH2 domain. D. STAT5b mutations in the SH2 domain. E. Table showing T/NK-PTLD subtypes with STAT3 or 5b mutations, and 17q copy number changes. F. Ideogram of copy number changes detected in 16 cases of T/NK-PTLD. Gains are indicated in blue, losses in red and LOH in green.

Table 2. Genomic alterations in T/NK-PTLDs.

Case Subtype Gain/Loss Locus Base Positions Size (mb) Total Genes Genes identified in Cancer Gene Census
1 PTCL, NOS Not analyzed
2 PTCL, NOS Loss 7p22.1p15.3 chr7:6,327,460-23,472,983 17.14Mb 85 1(ETV1)
3 PTCL, NOS Gain 9p24.3p24.1 chr9:681,960-7,237,233 6.5mb 42 2 (JAK2, CD274)
Gain 11q22.3q25 chr11:105,115,252-135,006,516 29.89 304 11 (ATM, DDX10, POU2AF1, SDHD, PAFAH1B2, PCSK7, MLL, DDX6, ARHGEF12, FLI1)
Loss 6q11.1q27 chr6:62,173,195-170,837,508 108.66 561 10 (PRDM1, ROS1, GOPC, STL, MYB, TNFAIP3, ECT2L, EZR, FGFR1OP, MLLT4)
4 PTCL, NOS Loss 20q13.13q13.2 Chr20:48,080,029-51,759119 3.42Mb 33 None
5 PTCL, NOS Gain 4q28.1q34.1 chr4:125,081,373-175,395,062 50.31Mb 180 19(FBXW7)
Gain 14q31.1q32.33 chr14:83,163,335-106,495,970 23.33Mb 294 8 (TRIP11, GOLGA5, DICER1, TCL6, TCL1A, BCL11B, AKT1, IGH)
LOH 10q23.32q25.1 chr10:92,990,108-106,337,119 13.34 196 3 (TLX1, NFKB2, SUFU)
Loss 17p13.3p11.2 chr17:400,959-21,516,719 21.11Mb 419 6 (YWHAE, USP6, TP53, PER1, GAS7, MAP2k4)
6 EBV+ PTCL Gain 2q14.2q37.3 chr2:120,196,122-243,199,373 123.00Mb 803 13(ERCC3, CHN1, HOXD13, HOXD11, NFE2L2, PMS1, SF3B1, CREB1, IDH1, ATIC, FEV, PAX3, ACSL3)
Gain 3p26.1p14.3 chr3:7,153,652-58,391,565 51.23Mb 528 12(SRGAP3, FANCD2, VHL, PPARG, RAF1, XPC, MLH1, MYD88, CTNNB1, SETD2, BAP1, PBRM1)
Loss 6q11.2q24.2 chr6:57,730,420-143,488,404 85.75Mb 370 7(PRDM1, ROS1, GOPC, STL, MYB, TNFAIP3, ECT2L)
LOH 17q21.2q25.3 chr17:40,324,798-80,263,427 39.93Mb 678 14(BRCA1, ETV4, COL1A1, HLF, MSI2, CLTC, BRIP1, CD79B, DDX5, PRKAR1A, SRSF2, CANT1, ASPSC, STAT3)
LOH 9q33.3q34.13 chr9:126,794,173-135,302,624 8.5 144 4 (SET, FNBP1, ABL1, NUP214)
LOH 15q23q25.1 chr15:71,689,059-79,548,077 7.85 121 1 (PML)
Loss Xp22.33q28 chrX:177,942-155,219,364 155.04Mb 1285 CRLF2, P2RY8, ZRSR2, BCOR, KDM6A, SSX1, WAS, GATA1, TFE3, SSX2, KDM5C, MSN, MED12, NONO, ATRX, SEPT6, ELF4, GPC3, PHF6, MTCP1)
7 HSTCL Gain 1q21.3 - q25.2 chr1:154,087,033-176,562,796 22.47576 369 7 (TPM3, MUC1, PRCC, NTRK1, SDHC, FCGR2B, PBX1)
Loss 4p15.32 - p15.2 chr4:16,152,859-25,102,176 8.949318 29 None
Loss 4q13.1 - q23 chr4:62,726,234-100,740,709 38.01448 230 1 (RAP1GDS1)
Loss 7p22.2 - p11.1 chr7:3,896,634-61,064,518 57.16789 373 9 (PMS2, ETV1, HNRNPA2B1, HOXA9, HOXA11, HOXA13, JAZF1, IKZF1, EGFR)
Gain 7q11.22 - q21.11 chr7:70,468,676-77,724,388 7.255713 103 2 (ELN, HIP1)
LOH 7q31.1 - q36.3 chr7:110,440,775-159,118,443 48.7 401 7 (MET, SMO, CREB3L2, KIAA1549, BRAF, EZH2, MLL3)
Gain 8q11.21 - q24.3 chr8:51,192,818-146,364,002 95.2 571 10 (TCEA1, PLAG1, CHCHD7, NCOA2, HEY1, COX6C, EXT1, MYC, NDRG1, RECQL4)
LOH 11q13.3q25 chr11:70,834,389-135,006,516 64.2 559 15 (NUMA1, PICALM, MAML2, BIRC3, ATM, DDX10, POU2AF1, SDHD, PAFAH1B2, PCSK7, MLL, DDX6, CBL, ARHGEF12, FLI1)
Gain 17q21.31-q25.3 chr17:41,516,675-80,366,217 16.8 634 12 (ETV4, COL1A1, HLF, MSI2, CLTC, BRIP1, CD79B, DDX5, PRKAR1A, SRSF2, CANT1, ASPS)
Gain 22q12.3 - q13.33 chr22:32,252,434-51,304,566 19.1 302 4 (MYH9, PDGFB, MKL1, EP300)
Homozygous loss Yp11.31 - q11.23 chrY:2,660,163-28,799,935 26.1 189 None
8 HSTCL Loss 7p22.3p11.2 chr7:41,421-55,272,715 55.23Mb 396 8(CARD11, PMS2, ETV1, HNRNPA2B1, HOXA9, HOXA11, HOXA13, JAZF1, IKZF1, EGFR)
Gain 7q11.21q36.3 chr7:61,816,116-159,118,443 97.3 838 12(SBDS, ELN, HIP1, AKAP9, CDK6, MET, SMO, CREB3L2, KIAA1549, BRAF, EZH2, MLL3)
9 HSTCL No changes identified.
10 AITL Loss 1p31.3 - p31.1 chr1:66,994,889-80,226,910 13.2 72 1 (FUBP1)
Loss 1p13.3 - p11.2 chr1:109,527,108-121,350,934 11.0 151 5 (RBM15, TRIM33, NRAS, FAM46C, NOTCH2)
Loss 2q11.1 - q14.1 chr2:95,439,005-116,163,121 20.7 210 2 (TTL, PAX8)
Loss 2q14.1 - q23.1 chr2:117,810,213-149,194,919 31.4 138 1 (ERCC3)
LOH 4p16.3 - q35.2 chr4:71,566-190,915,650 190.8 1034 13 (FGFR3, WHSC1, SLC34A2, PHOX2B, FIP1L1, PDGFRA, CHIC2, KIT, KDR, RAP1GDS1, TET2, IL2, FBXW7)
Gain 5q31.1 - q31.2 chr5:130,788,642-138,657,896 7.9 102 None
Loss 5q31.2 - q32 chr5:138,689,223-149,136,632 10.4 165 None
Loss 5q33.3 - q34 chr5:157,096,900-160,315,446 3.2 25 1 (EBF1)
Gain 5q35.1 - q35.2 chr5:170,275,961-172,901,400 2.6 24 3 (RANBP17, TLX3, NPM1)
Gain 6p25.3 - p25.1 chr6:204,909-5,172,009 5.0 48 1 (IRF4)
LOH 6p25.3 - p21.1 chr6:5211336-45699405 40.5 628 10 (DEK, HIST1H4I, TRIM27, POU5F1, DAXX, HMGA1, FANCE, PIM1, TFEB, CCND3)
Gain 7p22.3 - p15.3 chr7:41,421-22,798,650 22.8 159 3 (CARD11, PMS2, ETV1)
Gain 7q21.11 - q31.31 chr7:80,054,945-119,098,598 39.0 317 3 (AKAP9, CDK6, MET)
Gain 7q36.2 - q36.3 chr7:154,693,849-157,479,833 2.8 26 None
Loss 8p23.3 - p23.1 chr8:172,417-7,004,147 6.8 47 None
Gain 8q22.2 - q24.11 chr8:99,374,877-117,703,509 18.3 66 1 (COX6C)
Gain 9q21.11 - q34.3 chr9:71,043,202-141118911 70.1 730 15 (GNAQ, SYK, OMD, FANCC, XPA, NR4A3, TAL2, SET, FNBP1, ABL1, NUP214, TSC1, RALGDS, BRD3, NOTCH1)
Gain 11q13.4 - q25 chr11:71,703,483-134,938,847 63.2 543 15 (NUMA1, PICALM, MAML2, BIRC3, ATM, DDX10, POU2AF1, SDHD, PAFAH1B2, PCSK7, MLL, DDX6, CBL, ARHGEF12, FLI1)
LOH 16p13.3 - p13.2 chr16:83,887-8,065,382 8.0 235 2 (TSC2, CREBBP)
LOH 17p13.3 - p11.2 chr17:400,959-16,277,578 15.9 319 6 (YWHAE, USP6, TP53, PER1, GAS7, MAP2K4)
Loss 17q24.3 - q25.3 chr17:67,876,646-76,799,898 8.6 145 1 (SRSF2)
Loss 17q25.3 chr17:79,372,489-80,263,427 0.9 44 1 (ASPSCR1)
Gain 22q12.1 - q12.3 chr22:27,148,121-35,540,423 8.4 100 4 (MN1, CHEK2, EWSR1, NF2)
Gain Xp22.33 chrX:177,942-2,000,942 1.8 15 2 (CRLF2, P2RY8)
Loss Xp22.2 chrX:10,983,386-12,957,293 2.0 9 None
LOH Xp22.33 - p11.1 chrX:177,942-155,219,364 155.0 1286 21 (CRLF2, P2RY8, ZRSR2, BCOR, KDM6A, SSX1, SSX4, WAS, GATA1, TFE3, SSX2, KDM5C, MSN, MED12, NONO, ATRX, SEPT6, ELF4, GPC3, PHF6, MTCP1)
Loss Xp21.3 - p11.3 chrX:28,468,750-43,844,600 15.4 57 1 (BCOR)
Gain Xp11.3 - p11.22 chrX:43,851,171-53,446,146 9.6 221 8 (KDM6A, SSX1, SSX4, WAS, GATA1, TFE3, SSX2, KDM5C)
Loss Xq21.31 - q22.3 chrX:90,213,826-105,763,052 15.5 90 None
Loss Xq23 - q25 chrX:112,406,196-121,321,850 8.9 162 1 (SEPT6)
Loss Xq27.3 - q28 chrX:143,811,457-155,219,364 11.4 209 1 (MTCP1)
11 AITL No changes identified.
12 c-ALCL Gain 6q21-q24.1 chr6:109,262,907-142,278,857 33.0 30 2 (ROS1, GOPC)
LOH 17p13.3-12 chr17:1-15,645,289 15.6 315 6 (YWHAE, USP6, TP53, PER1, GAS7, MAP2K)
13 c-ALCL Gain 1p36.22p36.21 chr1:9,744,244-13,187,252 3.44Mb 72 None
Gain 10p15.3p12.2 chr10:126,070-23,745,727 23.61Mb 160 2(GATA3, MLLT10)
Loss 13q13.1q34 chr13:32,540,047-115,103,150 82.56Mb 438 5(BRCA2, LHFP, LCP1, RB1, ERCC5)
Loss 16q12.1q23.2 chr16:49,691,925-80,146,038 30.45Mb 303 6 (CYLD, HERPUD1, CDH11, CBFB, CDH1, MAF)
Loss 16q23.3q24.1 chr16:82,431,694-86,293,870 3.86Mb 41 None
14 c-ALCL Not analyzed
15 ENKTCL Gain 2q24.3q32.3 chr2:164,197,701-195,534,597 31.33 Mb 183 5 (CHN1, HOXD13, HOXD11, NFE2l2, PMS1)
LOH 2q33.1-q37.3 chr2:198,858,917-243,052,331 44.19Mb 401 6 (CREB1, IDH1, ATIC, FEV, PAX3, ACSL3)
Loss 3p13p12.3 chr3:69,852,242-79,214,617 9.36 29 2(MITF, FOXP1)
Loss 4q32.3q35.2 chr4:166,281,785-190,915,650 24.6 98 None
Gain 5q21.3q35.3 chr5:105,294,321-180,698,312 75.4 62 9 (APC, PDGFRB, CD74, ITK, EBF1, RANBP17, TLX3, NPM1, NSD1)
Gain 6p25.3p24.3 chr6:204,909-9,047,746 8.84Mb 67 1 (IRF4)
Loss 6q16.3q23.3 chr6:101,280,508-138,764,089 37.43 204 None
Gain 9q13q34.12 chr9:68,170,421-133,962,930 65.79 559 10 (GNAQ, SYK, OMD, FANCC, XPA, NR4A3, TAL2, SET, FNBP1, ABL1)
Loss 12q24.33 132,663,422-133,818,115 1.15kb 23 None
Loss 15q24.1q26.2 chr15:73,313,691-97,999,066 24.68Mb 281 5(PML, NTRK3, IDH2, CRTC3, BLM)
Loss 17p13.3p11.2 chr17:400,959-20,301,297 19.90Mb 403 7 (YWHAE, USP6, TP53, PER1, GAS7, MAP2K4, STAT3)
Loss 17q24.1q24.2 chr17:62,680,553-64,867,456 2.1Mb 179 None
Loss 17q11.2q25.3 Chr17:25,899,925-79,934,193 54.09Mb 1034 21 (NF1, SUZ12, TAF15, MLLT6, LASP1, CDK12, ERBB2, RARA, BRCA1, ETV4, COL1A1, HLF, MSI2, CLTC, BRIP1, CD79B, DDX5, PRKAR1A, SRSF2, CANT1, ASPSCR1)
Loss 18p11.32q23 Chr18:128,557-77,991,543 77.86Mb 382 4 (ZNF521, SS18, MALT1, BCL2)
Loss 19p13.3 chr19:247,232-2,303,276 2.0MB 92 3(FSTL3, STK11, TCF3)
Gain Xq27.3q28 chrX:146,155,369-155,219,364 9.06Mb 195 1(MTCP1)
16 ENKTCL Not analyzed
17 ATLL No changes identified.
18 LYP No changes identified.
19 PTCL, NOS Gain 1q21.1 - q32.1 chr1:144,940,761-206,669,136 61.7 859 15 (PDE4DIP, BCL9, ARNT, TPM3, MUC1, PRCC, NTRK1, SDHC, FCGR2B, PBX1, ABL2, TPR, MDM4, ELK4, SLC45A3)
LOH 3p26.3 - p21.1 chr3:63,411-52,826,707 52.8 510 12 (SRGAP3, FANCD2, VHL, PPARG, RAF1, XPC, MLH1, MYD88, CTNNB1, SETD2, BAP1, PBRM1)
Loss 7p22.3 - p11.2 chr7:1-57,754,465 58.0 422 10 (CARD11, PMS2, ETV1, HNRNPA2B1, HOXA9, HOXA11, HOXA13, JAZF1, IKZF1, EGFR)
Gain 7q11.21-q34 chr7:62827731-142378708 79.6 658 10 (SBDS, ELN, HIP1, AKAP9, CDK6, MET, SMO, CREB3L2, KIAA1549, BRAF)
Gain 8p23.3q24.3 chr8:172,417-146,292,734 146.1 966 15 (WHSC1L1, FGFR1, HOOK3, TCEA1, PLAG1, CHCHD7, PCM1, WRN, NCOA2, HEY1, COX6C, EXT1, MYC, NDRG1, RECQL4)
Open in a new tab

LOH: Loss of heterozygosity

Targeted next generation sequencing

Somatic mutations were detected in 17/18 cases (94%) using targeted sequencing of 465 cancer associated genes. Overall, 377 variants were identified: 286 missense (76%), 31 indels (8%), 16 nonsense (4%), and 44 intronic (12%) (Suppl. Table 1), with an average of 594.8-fold coverage and > 10X coverage for 99% of the coding regions (Suppl. Table 2). The pathogenic variants, focusing on genes recurrently targeted or implicated in hematologic malignancies, are listed in Figure 2.

Figure 2. Selected mutations identified by next-generation sequencing in 18 cases of T/NK-PTLD.

Figure 2

Open in a new tab

Total number of subjects with mutations is listed at right. A green box indicates mutation co-occurring with genomic loss or LOH, yellow box indicates MSI-H status as a consequence of mutation and grey columns indicate 3 EBV+ PTLD.

Heterozygous mutations of epigenetic modifier genes were the most frequently observed alterations (11/18, 61%). TET2 mutations were seen in four cases; missense (n = 2, including R1359G), frameshift (n = 1), and nonsense accompanied by LOH of 4q24 (n = 1, R544X). Mutations in histone and DNA methyltransferases (KMT2D, KMT2C, DNMT3A) and the histone demethylase (KDM6B) occurred in 7/18 (39%) cases. Missense and frameshift mutations in chromatin remodeling complex genes (ARID1B, ARID2) were seen in 5 (28%) cases.

Disruption of TP53 was identified in 6 of 18 (33%) cases (Figure 3A, 3B). Biallelic inactivation was noted in 3 cases (co-occurrence of mutation with 17p LOH) and monoallelic missense mutations in two cases. All missense mutations (n = 4) are classified as non-functional or partially functional in the IARC TP53 database (Version R17). [5] Deletion of 17p encompassing the TP53 locus alone was seen in one case.

Alterations of JAK/STAT pathway genes were seen in 5 of 18 cases (28%). STAT3 and STAT5B mutations were mutually exclusive (Figure 3C-3E). STAT5B mutations were present in one case each of HSTCL and PTCL, NOS. STAT3 mutations were present in one case each of c-ALCL, ENKTCL, and the EBV+ PTCL. LOH of the STAT3 locus on 17q was observed in the two EBV+ PTLDs with STAT3 mutations (EBV+ PTCL and ENKTCL), suggesting biallelic gain of function. These two cases also had loss of 6q encompassing FOXO3, PRDM1 and PTPRK. A JAK3 variant (S568P) adjacent to a previously described hotspot was also present in the STAT3-mutated EBV+ PTCL. [6]

Subtype-specific genetic alterations were also identified. One of the two cases of angioimmunoblastic T-cell lymphoma demonstrated known pathogenic mutations in RHOA and FYN, proteins involved in T-cell motility and proliferation and TCR signaling. [7]

Importantly, mutations in genes not previously implicated in PTCL pathogenesis were also observed. Missense mutations in MED12 were seen in 3 cases (1 PTCL, NOS and 2 HSTCL), including two novel and potentially damaging variants (R516H and R816Q) and one exon 2 mutation (L36P). Alterations of TBX3 were observed in 3 of 5 PTCL, NOS. A missense mutation in MTOR (W1456L) involving the FAT domain was observed in the EBV+ PTCL. A three base pair insertion mutation was observed in FBXW7 in one PTCL, NOS, which was confirmed by Sanger sequencing (Suppl. Figure 1).

Microsatellite instability

Variants in mismatch repair (MMR) genes were detected in 4 of 18 PTLD (cases 1, 2, 8, and 15, Figure 2). However only one (6%) PTLD (case 2) with a heterozygous PMS2 mutation and PMS2 loss by immunohistochemistry showed evidence of high level microsatellite instability (MSI-H); alterations at 5/5 mononucleotide repeats accounting for 7% (1/14) of all cases analyzed with a panel of microsatellite markers. The remaining 3 cases showed normal immunohistochemical expression of the MMR gene products.

DISCUSSION

Our series of T/NK-PTLD comprised a spectrum of PTCL subtypes that have been reported to occur post organ transplantation and are recognized as monomorphic PTLDs in the 2008 WHO classification [3, 4]. Epidemiologic data drawn from national registries have shown a higher frequency of PTCL, NOS, ALCL, HSTCL, and ENKTCL in transplant recipients. [8] Data regarding other PTCL subtypes in the setting of immunosuppression (e.g. AITL, ATLL) are limited. [9, 10] Cases of ATLL, however, have been reported in recipients of solid organ allografts in multiple series. [11, 12] In fact, immunosuppression has been proposed as a risk factor for neoplastic transformation in HTLV-1 carriers post organ transplantation. [13] Our observations support the broad definition of T/NK-PTLD in the current WHO classification and suggest inclusion of more detailed phenotypic information in PTLD databases, which will allow precise classification of PTCL and help determine the role of immune deregulation in the pathogenesis of different disease subtypes.

The clinicopathological features of T/NK-PTLD are distinct from B-cell PTLDs. In contrast to B-cell PTLDs, which are EBV-driven in 55-65% of cases, only 3 of 19 (16%) T/NK-PTLD in our series showed evidence of EBV infection. [14] Consistent with prior reports, disease presentation was late after transplant, with a median of 7 years between onset of immunosuppression and the development of lymphoma. The time of occurrence of B-cell PTLDs has an apparent bimodal distribution with the largest peak occurring in the first year after transplantation and a smaller peak observed five years after transplantation. [8] While a subset of B-cell PTLDs respond to reduction in immunosuppression, the majority of the T/NK-cell PTLDs do not, and they are associated with poor outcomes despite aggressive treatment. [15] Disease biology, however, appears to mirror the subtype specific differences observed in T-cell lymphomas of immunocompetent individuals. Lymphomatoid papulosis followed a fairly indolent course with survival over 10 years, while ENKTCL and HSTCL were rapidly fatal.

The genomic alterations detected in our cohort were similar to those described in PTCLs occurring in immunocompetent hosts. [16, 17] Changes consistent with isochromosome 7q, a characteristic feature of HSTCL, were identified in 2 cases of HSTCL. Loss of 13q, encompassing ING1 and 16q, encompassing the CTCF locus, seen in one c-ALCL, have been reported in non-transplant associated c-ALCL. [18] One of two ENKTCL and the EBV+ PTCL showed loss of 6q. This recurrent abnormality, which is observed in 29-52% of ENKTCL arising in immunocompetent individuals, encompasses loci of the FOXO3 and PRDM1 genes, which have been shown to function as tumor suppressors in ENKTCL and subtypes of PTCL. [16, 19, 20] In contrast to EBV+ B-PTLD, however, we observed a higher frequency of complex copy number changes in EBV+ T-PTLD. [21]

Mutations of epigenetic modifier genes were the most frequent alterations (61%) in T/NK-PTLD and were most commonly observed in cases of PTCL, NOS and AITL. A similar mutational spectrum is frequently observed in PTCL occurring in immunocompetent individuals. [7, 22, 23] Loss of function mutations in KMT2D/MLL2, a lysine specific histone methyltransferase targeting H3K4 residues that is considered to function as a tumor suppressor, have been reported in PTCL arising in immunocompetent individuals and were seen in a variety of T/NK-PTLD. [24] Missense mutations in TET2, a methylcytosine dioxygenase that plays an important role in active DNA demethylation, are frequent in both PTCL, NOS and AITL (38% and 33-76%, respectively). [23, 25, 26] Loss of function mutations in DNMT3A, a DNA methyltransferase that is required for genome-wide de novo methylation, are frequent in a variety of malignancies and have been reported in up to 38% of PTCL, NOS and 33%-37% AITL. [23, 26, 27] In a murine model, the combination of TET2 loss and DNMT3A mutation appeared to cooperate in the development of T-cell lymphomas exhibiting features of AITL. [28] Similar to observations in PTCL, NOS and AITL occurring in immunocompetent individuals, concomitant TET2 and DNMT3A mutations were noted in two cases of PTCL, NOS in our series. [29] Mutations in chromatin modifier genes, including ARID1B, and ARID2, were also common, a finding in line with prior studies of PTCL occurring in immunocompetent hosts. [24]

The TP53 pathway is frequently dysregulated in a variety of neoplasms, most commonly by TP53 mutation or loss, and these lesions are associated with aggressive disease. [30] TP53 abnormalities are known recurrent changes in a variety of PTCL, albeit at a low frequency (8-9%) and their prognostic significance is unclear in these neoplasms. [31–33] The higher frequency of TP53 aberrations in our series (33%) could reflect the small sample size and future larger studies are warranted to determine if the frequency of this genetic lesion is higher in PTCL arising in states of immune dysregulation.

Alterations of the JAK/STAT pathway are frequent in diverse subtypes of PTCL of immunocompetent hosts, including ALCL, HSTCL, T-PLL, ENKTCL, and also in LGL. [6, 34–37] Genetic aberrations activating the JAK-STAT pathway were identified in 28% of T/NK-PTLD, including PTCL, NOS, HSTCL, c-ALCL, and ENKTCL, and an EBV+ PTCL. As previously observed in PTCL, STAT3 and STAT5b alterations were mutually exclusive in T/NK-cell PTLD as well. [38] We observed an association between EBV infection and STAT3 activation. STAT3 mutations and LOH of the STAT3 locus were seen in 2 of 3 EBV+ T/NK-PTLDs with concomitant loss of 6q encompassing PTPRK. Loss of PTPRK has been associated with constitutive STAT3 activation in ENKTCL. [39] Activation of STAT3 by EBV, even in the absence of genetic lesions, has been shown to induce lymphoproliferative disorders of T- and NK-cells. [40] EBNA-2 is a coactivator of STAT3 transcription and LMP1 is known to constitutively activate STAT3 in B-cells. [41, 42] Of interest, IFN-gamma induced by LMP1 has been shown to enhance STAT1 expression in EBV+ B-PTLD. [43] Whether analogous mechanisms are operational in EBV-associated T/NK-PTLD is not yet known. Nonetheless, our findings suggest that targeting the JAK-STAT pathway with currently available drugs or more selective agents might be of therapeutic benefit in a subset of T/NK-PTLD.

Mutations in genes not previously described in PTCL were also observed. Novel and potentially damaging variants in MED12 were observed in two cases and a MED12 exon 2 mutation (L36P), recently described in chronic lymphocytic leukemia, was seen in one case. [44] MED12 is part of the CDK8 subcomplex, which includes CDK8 kinase and cyclin C, of Mediator, a component of the preinitiation complex, with integral roles in transcriptional regulation. [45] The MED12 protein has been shown to regulate JAK/STAT signaling in mouse embryonic fibroblasts [46]. The role of MED12 in normal and neoplastic T-cells, however, is unclear. The functional consequence of mutations of the transcription factor T-box 3 (TBX3), a transcriptional repressor, important for myriad developmental processes, [47] noted in three cases, is also not known at present. A novel missense mutation in MTOR was detected in an EBV+ PTCL. Similar mutations, which have been shown to activate both mTORC1 and 2 signaling in other neoplasms, may contribute to T-cell growth, survival and proliferation, in part by metabolic reprogramming of lymphocytes. [48] Activation of the mTOR pathway has been reported in T-cell lymphomas, but the presence of mTOR mutations has not been systematically investigated in these malignancies. Of interest, rapamycin analogues, which disrupt the mTORC signaling cascade have shown promise in early phase clinical trials of PTCL patients. [49–51]

Azathioprine use has been associated with an increased risk of hematological malignancies in allograft recipients and individuals with autoimmune diseases. [52] Thiopurines have been implicated in MMR pathway defects possibly due to epigenetic silencing of the MMR enzymes. [53] Borie et al. reported microsatellite instability (MSI-H) in 9% of immunosuppression-related lymphomas, including 33% (6/18 cases) of PTCL post solid organ transplantation. [52] Only 1 of 10 patients in our series treated with an azathioprine-based immunosuppressive regimen developed a MSI-H tumor. Although the observed frequency of MSI-H was lower in our series (1/14 cases; 7%) than a prior study, this difference was not statisically significant (p = 0.1).

In summary, our study represents the first survey of the genetic landscape of T/NK-PTLDs and adds to the growing list of genes altered in T-cell neoplasms that affect a variety of T-cell functions, including activation, proliferation, epigenetic regulation and metabolism. The observed clinicopathologic features and genetic aberrations appear similar to those reported for PTCL subtypes occurring in “immunocompetent” individuals, suggesting shared pathogenetic mechanisms. Our findings raise the possibility of novel therapeutic options for these aggressive lymphomas that need to be explored further in pre-clinical studies.

MATERIALS AND METHODS

Case selection

The archives of the Departments of Pathology, Columbia University Medical Center, New York and University Hospitals of KU, Leuven were searched for cases of T/NK-PTLD. Nineteen cases were identified (Columbia University Medical Center, n = 14; University Hospitals of KU, Leuven, n = 5) that had adequate formalin-fixed, paraffin-embedded (FFPE) tissue for analysis (> 50% tumor, except for one case of lymphomatoid papulosis with a tumor burden of 20%). We defined T/NK-PTLD as T- or NK-cell lymphomas occurring in individuals after organ transplantation, in accordance with the WHO 2008 guidelines. Morphologic and phenotypic data were reviewed and the lymphomas were classified according to current WHO criteria. [1] Patient demographic and clinical data were collected from the electronic medical record. This study was approved by the Institutional Review Board of Columbia University and performed in accordance with the Declaration of Helsinki.

Whole genome copy number and LOH analysis

Genome-wide copy number and LOH analysis was performed for 16 cases using the Affymetrix OncoScan FFPE assay (Affymetrix, CA, USA). Briefly, the Oncoscan assay has been optimized to work with DNA from FFPE tissue, utilizing molecular inversion probes to identify changes in copy number and loss of heterozygosity. [54] DNA extraction, sample preparation, hybridization, and scanning were performed according to the manufacturer's specifications. Analysis was performed using the Affymetrix Chromosome Analysis Suite 2.0 (ChAS) and Nexus Copy Number 7.5 software (Biodiscovery, Inc. CA, USA).

All copy number alterations and regions of LOH called by the software were verified manually to determine erroneous calls and identify clonal gains and losses undetected by the software(s). Analysis was restricted to gains and losses > 1 Mb in length. Genomic alterations are reported based on the NCBI build 37 (hg19) of the human genome and cancer-associated genes were curated from the Cancer Gene Census (COSMIC v61 Release;http://www.sanger.ac.uk/genetics/CGP/Census/).

Next generation sequencing analysis

Targeted next generation sequencing of 18 tumors and 9 matched normal samples was performed using a panel comprising 465 cancer-associated genes (Suppl. Table 3). Fifty to 250 ng of DNA, extracted using the Qiamp mini kit or the Qiamp FFPE kit (Qiagen, Germantown, USA) was fragmented to a median of 150-200bp, by sonication. Following end-repair and 3′ adenylation of the fragments, and ligation of double-stranded sequencing and indexing adaptors to both ends, target capture and enrichment was performed with the Sure Select Hybrid Capture system (Agilent Technologies, Santa Clara, USA), using custom designed probes. Libraries were then quantified using qPCR, diluted to 2nM and pooled, prior to cluster generation and analysis on Illumina HiSeq2500, using Illumina TruSeq v3 chemistry (San Diego, USA) and 100bp paired-end reads (up to 9 indexed samples per run). Fastq files (more than 70% of reads with > Q30) were demultiplexed with CASAVA, and samples with at least 6Gb of sequencing data were used for mapping and variant calling using NextGene Software (Softgenetics, State College, USA). Reads were aligned to the hg19 (GRCh37) reference genome. At least 3 variant reads were required to call a variant. All calls with ambiguous alignments were excluded, including calls corresponding to regions with large indels. Candidate variants at very low allele frequency (< 10% of variant reads) were eliminated.

After annotation, the variants were cross referenced with those in the 1000 Genomes Project, OMIM, dbSNP, and the Exome Variant Server. Variants with an allele prevalence > 1% in the 1000 genomes project were excluded. Common variants present in our departmental database of variants identified in prior constitutional exome analysis, non-pathogenic variants reported in dbSNP, and low quality calls were filtered out. The remaining variants were submitted for manual curation and variant prioritization with visual review of alignments. Synonymous variants and intronic variants greater than 2 bp from the coding sequence were excluded. Variants were manually cross-referenced with the Catalog of Somatic Variants in Cancer (COSMIC) and those that were not known “hot spot” mutations or had not been previously reported as potential driver variants were analyzed by PROVEAN and SIFT algorithms. For cases with matched normal specimens, variants present in the normal samples were excluded.

Assessment of microsatellite instability

Microsatellite instability (MSI) testing was performed in 14 cases using a fluorescent PCR-based assay (MSI Analysis system, Version 1.2, Promega, Madison, WI). Briefly, this test assessed 5 mononucleotide repeats (BAT25, BAT26, NR-21, NR-24, and MONO-27) and 2 pentanucleotide repeats (PentaC and PentaD) on genomic DNA and matched normal, where available. The fluorescently labeled PCR products were analyzed by capillary gel electrophoresis. MSI was determined if the tumor alleles showed a size difference ≥3 bp. Tumors with 2 or more microsatellite unstable markers were classified as MSI-H; the remainder were classified as microsatellite stable (MSS). Immunohistochemistry was performed for MLH1 (clone M1, predilute, Ventana), MSH6 (clone 44, predilute, Ventana), MSH2 (clone G219-1129, predilute, Cell Marque) and PMS2 (clone EPR3947, predilute, Cell Marque) using an autostainer (Benchmark UltraTM Ventana, Tuscon, AZ) after heat induced antigen retrieval (EDTA, pH 7.3). The ultraViewTM Universal DAB Detection kit (Ventana) was used for visualization. Absence of nuclear staining was evaluated in lesional tissue; adjacent stromal cells were used as an internal control.

Methods for DNA extraction, immunohistochemistry, flow cytometry, and Sanger sequencing are described in the supplemental methods.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES

Footnotes

CONFLICTS OF INTEREST

The authors have no conflicts of interest to disclose.

GRANT SUPPORT

Thomas Tousseyn holds a Mandate for Fundamental and Translational Research from the “Stichting tegen Kanker” (2014-083). This study was funded by an intramural research grant provided by the Department of Pathology and Cell Biology, Columbia University Medical Center.

Editorial note

This paper has been accepted based in part on peerreview conducted by another journal and the authors' response and revisions as well as expedited peer-review in Oncotarget.

REFERENCES

  • 1.Swerdlow SH WS, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. pp. 343–349. [Google Scholar]
  • 2.Swerdlow SH. T-cell and NK-cell posttransplantation lymphoproliferative disorders. American journal of clinical pathology. 2007;127:887–895. doi: 10.1309/LYXN3RGF7D7KPYG0. [DOI] [PubMed] [Google Scholar]
  • 3.Herreman A, Dierickx D, Morscio J, Camps J, Bittoun E, Verhoef G, De Wolf-Peeters C, Sagaert X, Tousseyn T. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Leukemia & lymphoma. 2013;54:2190–2199. doi: 10.3109/10428194.2013.775436. [DOI] [PubMed] [Google Scholar]
  • 4.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon: IARC; 2008. [Google Scholar]
  • 5.Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human mutation. 2007;28:622–629. doi: 10.1002/humu.20495. [DOI] [PubMed] [Google Scholar]
  • 6.Lee S, Park HY, Kang SY, Kim SJ, Hwang J, Lee S, Kwak SH, Park KS, Yoo HY, Kim WS, Kim JI, Ko YH. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget. 2015;6:17764–17776. doi: 10.18632/oncotarget.3776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature genetics. 2014;46:166–170. doi: 10.1038/ng.2873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, Weisenburger DD, Martinez-Maza O, Hussain SK, Yang J, Chang ET, Engels EA. Risk of lymphoma subtypes after solid organ transplantation in the United States. British journal of cancer. 2013;109:280–288. doi: 10.1038/bjc.2013.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Hoshida Y, Li T, Dong Z, Tomita Y, Yamauchi A, Hanai J, Aozasa K. Lymphoproliferative disorders in renal transplant patients in Japan. International journal of cancer. 2001;91:869–875. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1125>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  • 10.Kraus TS, Twist CJ, Tan BT. Angioimmunoblastic T cell lymphoma: an unusual presentation of posttransplant lymphoproliferative disorder in a pediatric patient. Acta Haematologica. 2014;131:95–101. doi: 10.1159/000353783. [DOI] [PubMed] [Google Scholar]
  • 11.Yoshizumi T, Takada Y, Shirabe K, Kaido T, Hidaka M, Honda M, Ito T, Shinoda M, Ohdan H, Kawagishi N, Sugawara Y, Ogura Y, Kasahara M, Kubo S, Taketomi A, Yamashita N, et al. Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan. Journal of hepato-biliary-pancreatic sciences. 2016 doi: 10.1002/jhbp.345. [DOI] [PubMed] [Google Scholar]
  • 12.Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B. T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. British Journal of Haematology. 2004;127:429–432. doi: 10.1111/j.1365-2141.2004.05212.x. [DOI] [PubMed] [Google Scholar]
  • 13.Jenks PJ, Barrett WY, Raftery MJ, Kelsey SM, van der Walt JD, Kon SP, Breuer J. Development of human T-cell lymphotropic virus type I-associated adult T-cell leukemia/lymphoma during immunosuppressive treatment following renal transplantation. Clinical infectious diseases. 1995;21:992–993. doi: 10.1093/clinids/21.4.992. [DOI] [PubMed] [Google Scholar]
  • 14.Johnson LR, Nalesnik MA, Swerdlow SH. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. The American journal of surgical pathology. 2006;30:1604–1612. doi: 10.1097/01.pas.0000213317.59176.d2. [DOI] [PubMed] [Google Scholar]
  • 15.Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, Nguyen Quoc S, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. Journal of clinical oncology. 2001;19:772–778. doi: 10.1200/JCO.2001.19.3.772. [DOI] [PubMed] [Google Scholar]
  • 16.Hartmann S, Gesk S, Scholtysik R, Kreuz M, Bug S, Vater I, Doring C, Cogliatti S, Parrens M, Merlio JP, Kwiecinska A, Porwit A, Piccaluga PP, Pileri S, Hoefler G, Kuppers R, et al. High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus. British journal of haematology. 2010;148:402–412. doi: 10.1111/j.1365-2141.2009.07956.x. [DOI] [PubMed] [Google Scholar]
  • 17.Nakagawa M, Nakagawa-Oshiro A, Karnan S, Tagawa H, Utsunomiya A, Nakamura S, Takeuchi I, Ohshima K, Seto M. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clinical cancer research. 2009;15:30–38. doi: 10.1158/1078-0432.CCR-08-1808. [DOI] [PubMed] [Google Scholar]
  • 18.Sanchez-Schmidt JM, Salgado R, Servitje O, Gallardo F, Ortiz-Romero PL, Karpova MB, Zipser MC, Garcia-Muret MP, Estrach T, Rodriguez-Pinilla SM, Climent F, Suela J, Ferreira BI, Cigudosa JC, Salido M, Barranco C, et al. Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach. The Journal of investigative dermatology. 2011;131:269–271. doi: 10.1038/jid.2010.271. [DOI] [PubMed] [Google Scholar]
  • 19.Zettl A, Rudiger T, Konrad MA, Chott A, Simonitsch-Klupp I, Sonnen R, Muller-Hermelink HK, Ott G. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. The American journal of pathology. 2004;164:1837–1848. doi: 10.1016/S0002-9440(10)63742-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbo F, Piva R, Rancoita PM, Matolcsy A, Timar B, Tousseyn T, Rodriguez-Pinilla SM, Piris MA, Bea S, Campo E, Bhagat G, et al. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood. 2013;122:2683–2693. doi: 10.1182/blood-2013-04-497933. [DOI] [PubMed] [Google Scholar]
  • 21.Rinaldi A, Capello D, Scandurra M, Greiner TC, Chan WC, Bhagat G, Rossi D, Morra E, Paulli M, Rambaldi A, Rancoita PM, Inghirami G, Ponzoni M, Moreno SM, Piris MA, Mian M, et al. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. British Journal of Haematology. 2010;149:569–577. doi: 10.1111/j.1365-2141.2010.08125.x. [DOI] [PubMed] [Google Scholar]
  • 22.Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, Parrens M, Martin A, Xerri L, Brousset P, Chan LC, Chan WC, Gaulard P, Mak TW. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119:1901–1903. doi: 10.1182/blood-2011-11-391748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126:1741–1752. doi: 10.1182/blood-2015-05-644591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, Huberman K, Socci ND, Lailler N, Heguy A, Dolgalev I, Migliacci JC, Pirun M, Palomba ML, Weinstock DM, Wendel HG. Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. Leukemia. 2015;29:237–241. doi: 10.1038/leu.2014.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Lemonnier F, Couronne L, Parrens M, Jais JP, Travert M, Lamant L, Tournillac O, Rousset T, Fabiani B, Cairns RA, Mak T, Bastard C, Bernard OA, de Leval L, Gaulard P. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120:1466–1469. doi: 10.1182/blood-2012-02-408542. [DOI] [PubMed] [Google Scholar]
  • 26.Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123:1293–1296. doi: 10.1182/blood-2013-10-531509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R, Meyer MR, Erdmann-Gilmore P, Townsend RR, Wilson RK, Ley TJ. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer cell. 2014;25:442–454. doi: 10.1016/j.ccr.2014.02.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Scourzic L, Couronne L, Pedersen MT, Della Valle V, Diop M, Mylonas E, Calvo J, Mouly E, Lopez CK, Martin N, Fontenay M, Bender A, Guibert S, Dubreuil P, Dessen P, Droin N, et al. DNMT3A mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia. 2016 doi: 10.1038/leu.2016.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. The New England journal of medicine. 2012;366:95–96. doi: 10.1056/NEJMc1111708. [DOI] [PubMed] [Google Scholar]
  • 30.Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer research. 1994;54:4855–4878. [PubMed] [Google Scholar]
  • 31.Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. The American journal of pathology. 1994;144:573–584. [PMC free article] [PubMed] [Google Scholar]
  • 32.Rassidakis GZ, Thomaides A, Wang S, Jiang Y, Fourtouna A, Lai R, Medeiros LJ. p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. Leukemia. 2005;19:1663–1669. doi: 10.1038/sj.leu.2403840. [DOI] [PubMed] [Google Scholar]
  • 33.Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS, Ozsan N, Grebe SK, Frederick LA, Eckloff BW, Thompson EA, Kadin ME, Milosevic D, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120:2280–2289. doi: 10.1182/blood-2012-03-419937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Nicolae A, Xi L, Pittaluga S, Abdullaev Z, Pack SD, Chen J, Waldmann TA, Jaffe ES, Raffeld M. Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas. Leukemia. 2014;28:2244–2248. doi: 10.1038/leu.2014.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lopez C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, Johansson P, Ritgen M, Baumann T, Aymerich M, Jayne S, Russell RB, Campo E, Dyer MJ, Durig J, Siebert R. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. British journal of haematology. 2016;173:265–273. doi: 10.1111/bjh.13952. [DOI] [PubMed] [Google Scholar]
  • 36.Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, Lagstrom S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepisto M, Mattila P, Guinta K, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. The New England journal of medicine. 2012;366:1905–1913. doi: 10.1056/NEJMoa1114885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer cell. 2015;27:516–532. doi: 10.1016/j.ccell.2015.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Kucuk C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W, Lack N, Alkan C, Williams JC, Avery KN, Kavak P, Scuto A, Sen E, Gaulard P, Staudt L, Iqbal J, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nature communications. 2015;6:6025. doi: 10.1038/ncomms7025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Chen YW, Guo T, Shen L, Wong KY, Tao Q, Choi WW, Au-Yeung RK, Chan YP, Wong ML, Tang JC, Liu WP, Li GD, Shimizu N, Loong F, Tse E, Kwong YL, et al. Receptor-type tyrosine-protein phosphatase kappa directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma. Blood. 2015;125:1589–1600. doi: 10.1182/blood-2014-07-588970. [DOI] [PubMed] [Google Scholar]
  • 40.Honami Komatsu K, II, Haruna Shibayama, Tomotaka Yada, Momoko Yamada, Kouhei Yamamoto, MD,PhD, Takatoshi Koyama, MD, PhD, Shigeyoshi Fujiwara, MD,PhD, Osamu Miura, MD, PhD, Ayako Arai., MD, PhD . STAT3 Is Activated By EBV in T or NK Cells Leading to Development of EBV-T/NK-Lymphoproliferative Disorders American Society of Hematology. San Francisco: 2014. [Google Scholar]
  • 41.Shair KH, Bendt KM, Edwards RH, Bedford EC, Nielsen JN, Raab-Traub N. EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS pathogens. 2007;3:e166. doi: 10.1371/journal.ppat.0030166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Muromoto R, Ikeda O, Okabe K, Togi S, Kamitani S, Fujimuro M, Harada S, Oritani K, Matsuda T. Epstein-Barr virus-derived EBNA2 regulates STAT3 activation. Biochemical and biophysical research communications. 2009;378:439–443. doi: 10.1016/j.bbrc.2008.11.053. [DOI] [PubMed] [Google Scholar]
  • 43.Vaysberg M, Lambert SL, Krams SM, Martinez OM. Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma. American journal of transplantation. 2009;9:2292–2302. doi: 10.1111/j.1600-6143.2009.02781.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kampjarvi K, Jarvinen TM, Heikkinen T, Ruppert AS, Senter L, Hoag KW, Dufva O, Kontro M, Rassenti L, Hertlein E, Kipps TJ, Porkka K, Byrd JC, de la Chapelle A, Vahteristo P. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget. 2015;6:1884–1888. doi: 10.18632/oncotarget.2753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Turunen M, Spaeth JM, Keskitalo S, Park MJ, Kivioja T, Clark AD, Makinen N, Gao F, Palin K, Nurkkala H, Vaharautio A, Aavikko M, Kampjarvi K, Vahteristo P, Kim CA, Aaltonen LA, et al. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. Cell reports. 2014;7:654–660. doi: 10.1016/j.celrep.2014.03.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I, Dolken L, Strobl B, Muller M, Taatjes DJ, Kovarik P. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity. 2013;38:250–262. doi: 10.1016/j.immuni.2012.10.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Wansleben S, Peres J, Hare S, Goding CR, Prince S. T-box transcription factors in cancer biology. Biochimica et biophysica acta. 2014;1846:380–391. doi: 10.1016/j.bbcan.2014.08.004. [DOI] [PubMed] [Google Scholar]
  • 48.Ghosh AP, Marshall CB, Coric T, Shim EH, Kirkman R, Ballestas ME, Ikura M, Bjornsti MA, Sudarshan S. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. Oncotarget. 2015;6:17895–17910. doi: 10.18632/oncotarget.4963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yun S, Vincelette ND, Knorr KL, Almada LL, Schneider PA, Peterson KL, Flatten KS, Dai H, Pratz KW, Hess AD, Smith BD, Karp JE, Wahner Hendrickson AE, Fernandez-Zapico ME, Kaufmann SH. 4EBP1/c-MYC/PUMA and NFkappaB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood. 2016 doi: 10.1182/blood-2015-02-629485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Kim SJ, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, Do YR, Kang HJ, Eom HS, Ko YH, Lee SH, Yoo HY, Hong M, Suh C, Kim WS. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Annals of oncology. 2016;27:712–718. doi: 10.1093/annonc/mdv624. [DOI] [PubMed] [Google Scholar]
  • 51.Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic S, Nowakowski GS, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126:328–335. doi: 10.1182/blood-2015-02-629543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Borie C, Colas C, Dartigues P, Lazure T, Rince P, Buhard O, Folliot P, Chalastanis A, Muleris M, Hamelin R, Mercier D, Oliveira C, Seruca R, Chadburn A, Leblond V, Barete S, et al. The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. International journal of cancer. 2009;125:2360–2366. doi: 10.1002/ijc.24681. [DOI] [PubMed] [Google Scholar]
  • 53.Thiopurines Karran P. DNA damage, DNA repair and therapy-related cancer. British medical bulletin. 2006:79–80. doi: 10.1093/bmb/ldl020. 153-170. [DOI] [PubMed] [Google Scholar]
  • 54.Wang Y, Cottman M, Schiffman JD. Molecular inversion probes: a novel microarray technology and its application in cancer research. Cancer genetics. 2012;205:341–355. doi: 10.1016/j.cancergen.2012.06.005. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

oncotarget-07-37636-s001.pdf (501.2KB, pdf)
oncotarget-07-37636-s002.xlsx (56.6KB, xlsx)
oncotarget-07-37636-s003.xlsx (11KB, xlsx)
oncotarget-07-37636-s004.xlsx (13.1KB, xlsx)

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES